Opioids can enhance and inhibit the electrically evoked release of methionine-enkephalin.
The stimulated (40 Hz) release of enkephalin from the myenteric plexus can be modulated by multiple types of opiate receptor. The direction of the modulation is not fixed but is bimodal. Both an inhibition and an enhancement of evoked release is observed depending on the concentration of opioid agonist that is used. Each of these effects can be antagonized by naloxone. Following pretreatment of guinea pig myenteric plexus in vitro with forskolin (0.5 microM) or the lipid soluble cAMP analog 8-(4-chlorphenylthio)-cAMP (8-CPT-cAMP; 100 microM) the inhibition of stimulated Met-enkephalin release that is produced by sufentanil (10(-8) M), [D-Pen2-D-Pen5]enkephalin (DPDPE, 10(-8) M) or dynorphin (10(-7) M) is no longer observed. On the contrary, in forskolin- or 8-CPT-cAMP treated myenteric plexus a previously inhibitory concentration of the above opioids now produces an enhancement of the magnitude of the stimulated Met-enkephalin release. Excitatory responses (enhanced release) to lower concentrations of sufentanil (1 nM) or DPDPE (5 nM) are not affected by pretreatment with the same concentration of forskolin or 8-CPT-cAMP. These data suggest that the ability of opioids to enhance or inhibit evoked enkephalin release is mediated via different biochemical processes (separate second messenger systems). This could imply that the opioid enhancement of enkephalin release is due to a direct facilitation of release and not to disinhibition. The ability of opioids to enhance the release of at least some neurotransmitters should be taken into account when attempting to explain the physiological sequelae of the acute and chronic effects of narcotics.